142 related articles for article (PubMed ID: 31582553)
21. Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.
Chemnitz JM; von Lilienfeld-Toal M; Holtick U; Theurich S; Shimabukuro-Vornhagen A; Krause A; Brossart P; Hallek M; Scheid C
Ann Hematol; 2012 Jan; 91(1):47-55. PubMed ID: 21584670
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
23. Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.
Zohren F; Czibere A; Bruns I; Fenk R; Schroeder T; Gräf T; Haas R; Kobbe G
Bone Marrow Transplant; 2009 Dec; 44(12):785-92. PubMed ID: 19430496
[TBL] [Abstract][Full Text] [Related]
24. Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC.
Le Bourgeois A; Labopin M; Marçais A; de Latour RP; Blaise D; Chantepie S; N'Guyen S; Maillard N; Forcade E; Yakoub-Agha I; Huynh A; Marchand T; Bilger K; Ceballos P; Charbonnier A; Turlure P; Rubio MT; Béné MC; Guillaume T; Mohty M; Chevallier P;
Ann Hematol; 2020 Aug; 99(8):1855-1862. PubMed ID: 32564196
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia.
Kobos R; Steinherz PG; Kernan NA; Prockop SE; Scaradavou A; Small TN; Shukla N; Khalaf R; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2012 Mar; 18(3):473-80. PubMed ID: 22079789
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.
Oran B; Giralt S; Saliba R; Hosing C; Popat U; Khouri I; Couriel D; Qazilbash M; Anderlini P; Kebriaei P; Ghosh S; Carrasco-Yalan A; de Meis E; Anagnostopoulos A; Donato M; Champlin RE; de Lima M
Biol Blood Marrow Transplant; 2007 Apr; 13(4):454-62. PubMed ID: 17382251
[TBL] [Abstract][Full Text] [Related]
27. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.
Bornhäuser M; Kienast J; Trenschel R; Burchert A; Hegenbart U; Stadler M; Baurmann H; Schäfer-Eckart K; Holler E; Kröger N; Schmid C; Einsele H; Kiehl MG; Hiddemann W; Schwerdtfeger R; Buchholz S; Dreger P; Neubauer A; Berdel WE; Ehninger G; Beelen DW; Schetelig J; Stelljes M
Lancet Oncol; 2012 Oct; 13(10):1035-44. PubMed ID: 22959335
[TBL] [Abstract][Full Text] [Related]
28. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
[TBL] [Abstract][Full Text] [Related]
29. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
30. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study.
Bunjes D; Buchmann I; Duncker C; Seitz U; Kotzerke J; Wiesneth M; Dohr D; Stefanic M; Buck A; Harsdorf SV; Glatting G; Grimminger W; Karakas T; Munzert G; Döhner H; Bergmann L; Reske SN
Blood; 2001 Aug; 98(3):565-72. PubMed ID: 11468151
[TBL] [Abstract][Full Text] [Related]
31. Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms.
Monaco F; Scott BL; Chauncey TR; Petersen FB; Storer BE; Baron F; Flowers ME; Deeg HJ; Maloney DG; Storb R; Sandmaier BM
Haematologica; 2019 Jun; 104(6):1221-1229. PubMed ID: 30630975
[TBL] [Abstract][Full Text] [Related]
32. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
[TBL] [Abstract][Full Text] [Related]
33. Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.
Cruijsen M; Hobo W; van der Velden WJFM; Bremmers MEJ; Woestenenk R; Bär B; Falkenburg JHF; Kester M; Schaap NPM; Jansen J; Blijlevens NNM; Dolstra H; Huls G
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1000-1008. PubMed ID: 26860635
[TBL] [Abstract][Full Text] [Related]
34. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
Spitzer B; Jakubowski AA; Papadopoulos EB; Fuller K; Hilden PD; Young JW; Barker JN; Koehne G; Perales MA; Hsu KC; van den Brink MR; Kernan NA; Prockop SE; Scaradavou A; Castro-Malaspina H; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2088-2095. PubMed ID: 28711727
[TBL] [Abstract][Full Text] [Related]
35. Marrow versus blood-derived stem cell grafts for allogeneic transplantation from unrelated donors in patients with active myeloid leukemia or myelodysplasia.
Bertz H; Spyridonidis A; Ihorst G; Engelhardt M; Grüllich C; Wäsch R; Marks R; Finke J
Biol Blood Marrow Transplant; 2012 Jun; 18(6):894-902. PubMed ID: 22108569
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
37. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation.
de Lima M; Anagnostopoulos A; Munsell M; Shahjahan M; Ueno N; Ippoliti C; Andersson BS; Gajewski J; Couriel D; Cortes J; Donato M; Neumann J; Champlin R; Giralt S
Blood; 2004 Aug; 104(3):865-72. PubMed ID: 15090449
[TBL] [Abstract][Full Text] [Related]
38. Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Deeg HJ; Stevens EA; Salit RB; Ermoian RP; Fang M; Gyurkocza B; Sorror ML; Fatobene G; Baumgart J; Burroughs LM; Delaney C; Doney K; Egan DN; Flowers MED; Milano F; Radich JP; Scott BL; Sickle EJ; Wood BL; Yeung C; Storer BE
Biol Blood Marrow Transplant; 2018 May; 24(5):956-963. PubMed ID: 29274396
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
40. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission.
Pagel JM; Appelbaum FR; Eary JF; Rajendran J; Fisher DR; Gooley T; Ruffner K; Nemecek E; Sickle E; Durack L; Carreras J; Horowitz MM; Press OW; Gopal AK; Martin PJ; Bernstein ID; Matthews DC
Blood; 2006 Mar; 107(5):2184-91. PubMed ID: 16254140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
